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Donepezil, an acetylcholinesterase inhibitor, induces only moderate symptomatic effects
on memory in Alzheimer’s disease patients. An alternative strategy for treatment
of cognitive symptoms could be to act simultaneously on both histaminergic and
cholinergic pathways, to create a synergistic effect. To that aim, 14 month old C57/Bl6
mice were administered per oesophagy during nine consecutive days with Donepezil
(at 0.1 and 0.3 mg/kg) and S 38093 (at 0.1, 0.3, and 1.0 mg/kg), a H3 histaminergic
antagonist developed by Servier, alone or in combination and tested for memory
in a contextual memory task that modelized the age-induced memory dysfunction.
The present study shows that the combination of Donepezil and S 38093 induced
a dose-dependent synergistic memory-enhancing effect in middle-aged mice with a
statistically higher size of effect never obtained with compounds alone and without
any pharmacokinetic interaction between both compounds. We demonstrated that
the memory-enhancing effect of the S 38093 and Donepezil combination is mediated
by its action on the septo-hippocampal circuitry, since it canceled out the reduction
of CREB phosphorylation (pCREB) observed in these brain areas in vehicle-treated
middle-aged animals. Overall, the effects of drug combinations on pCREB in the
hippocampus indicate that the synergistic promnesiant effects of the combination on
memory performance in middle-aged mice stem primarily from an enhancement of
neural activity in the septo-hippocampal system.
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INTRODUCTION
The “cholinergic hypothesis” in aging or Alzheimer’s disease is based on the correlation between
the memory impairment and the decrease of the cholinergic function in the brain (Bartus et al.,
1982; Johannsson et al., 2015). Such correlation has also been observed in aged rodents (Fu et al.,
2014; Lim et al., 2015). The first clinical approach has thus consisted in inhibiting the decrease
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of acetylcholine (ACh) by blocking its degradation by
acetylcholinesterase (AChE) in the synaptic cleft (Marighetto
et al., 2008). Acetylcholinesterase inhibitors (AChEI), such as
Donepezil, are currently used in this way but are however
modestly effective in AD with only moderate cognitive
improvements (Lockhart and Lestage, 2003; Francis et al.,
2010).
In addition to deficits in ACh, histamine neurotransmission
is also reportedly diminished in elderly or in AD (Fernández-
Novoa and Cacabelos, 2001). Histamine has raised interest for
its implication in memory and attention (Witkin and Nelson,
2004; Schwartz, 2011). Among the four types of histaminergic
receptors, the H3 subtype, mainly presynaptic, is expressed
on neurons in the central nervous system (CNS), particularly
in brain areas involved in cognitive processes and arousal.
Expressed on histaminergic neurons, its activation leads to the
inhibition of the synthesis and release of histamine (Arrang
et al., 1983) and also negatively regulates the release of other
neurotransmitters such as ACh when H3 is expressed on
heterologous nerve endings (Blandina et al., 1996; Brown et al.,
2001). Thus, it has been argued that H3 antagonists, which
could hamper the constitutive negative feedback of H3 receptors
on the release of these neurotransmitters, would be valuable in
correcting cognitive deficiencies (Fox et al., 2003; Ligneau et al.,
2007; Femenía et al., 2015).
To that aim, S 38093 was developed by Servier. S 38093
is an inverse agonist/antagonist of H3 receptors, which has
shown procognitive properties at a mean pharmacological dose of
0.3 mg/kg (Panayi et al., 2014). Indeed, it improves performance
in episodic-like memory paradigm both in adult rats (object
recognition with natural forgetting or scopolamine-induced
amnesia) and aged mice (relational memory task). It is also
effective in working memory paradigms in middle-aged mice
(spontaneous alternation or concurrent serial alternation) and
in aged monkeys (delayed matching to sample task). These
effects are thought to be mediated by an enhanced release
of neurotransmitters especially ACh and histamine, which are
indeed observed by microdialysis in the prefrontal cortex (PFC)
and the hippocampus of rats after S 38093 administration (Panayi
et al., 2014)
An interesting alternative for treatment of cognitive decline
could be to act simultaneously on both histaminergic and
cholinergic pathways, to create a synergistic effect. Indeed,
combined treatments can be more effective than compounds
alone and can allow using lower doses of each compound,
i.e., minimizing the potential negative side effects. Therefore,
the aim of the present study was to investigate in a first
experiment the effect of the chronic administration of S
38093 and Donepezil, alone or in combination, in a model of
contextual memory impairments in middle-aged mice (Tronche
et al., 2010). In a second experiment, we measured the cAMP
response element binding protein (CREB) phosphorylation
as a marker of intracellular PKA activation and increased
neuronal activity after behavioral testing. Indeed, it has been
shown that memory consolidation relies on PKA activation
and subsequent CREB phosphorylation in the hippocampus
(Bernabeu et al., 1997; Colombo et al., 2003; Baudonnat et al.,
2011) whereas cognitive abilities involving mPFC are impaired
by PKA activation (Runyan and Dash, 2005; Barsegyan et al.,
2010). Therefore, CREB appears as a point of convergence for the
intraneuronal kinase/phosphatase balance, and reflects neuronal
activity sustaining memory processes (Benito and Barco, 2010).
MATERIALS AND METHODS
Animals
Animals were 12 months-old mice of the C57/Bl6 inbred strain
obtained from Charles River (L’Arbresle, France). They were
housed in collective cage in the colony room (12 h light–
dark cycle) until they were 14 months. Three weeks before the
experiments, they were housed individually. All procedures were
carried out during the light phase of the cycle, between 08:00
a.m. and 12:00 a.m. Three days before the acquisition phase of
memory testing and during the remaining behavioral phase, all
subjects were maintained at 85–90% of their ad libitum body
weight. All experiments were performed in accordance with
the local Ethics Committee for Animal Experiments and the
European Communities Council Directive of 1st February 2013
(2010/63/UE).
Memory Test
The memory task and apparatus has been fully described
previously (Chauveau et al., 2009). The contextual serial
discrimination (CSD) task is based on two successive
discriminations in a four-hole board which can be retrieved
with the help of specific temporal and contextual cues associated
with each of them. We already showed that unlike young mice,
middle-aged mice showed a deficit in this task (Béracochéa et al.,
2007, 2008, 2011; Tronche et al., 2010).
Acquisition Phase
The acquisition phase took place in room A where animals
learned two consecutive spatial discriminations (D1 and D2;
Figure 1A) which differed by the color and texture of the
floor and were separated by a 2-min delay interval. For both
D1 and D2, 10 20-mg food pellets were available during
the 6-min exploration sessions; for D2 specifically, the baited
hole was consistently located in the opposite symmetrical
hole. Environmental cues made of colored paper sheets were
positioned at 1.00 m above the board. At the end of the
acquisition phase, mice returned in the animal’s room for 24 h.
Animals retained for the test phase in the present study for both
Experiments 1 and 2 have eaten at least 7–8 pellets/10 during both
acquisitions.
Test Phase
Mice were replaced on the D1 floor in the board without any
pellet in the apparatus and were allowed to freely explore for
6 min during which the number of head-dips in each hole was
counted. This allowed measures of the % of “correct responses”
(head-dips into the hole previously baited on the same floor-
context), the % of “interference responses” (head-dips into
the hole previously baited at D2, on the other floor-context)
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FIGURE 1 | (A) Contextual serial discrimination: at the acquisition phase, mice performed two consecutive spatial discriminations varying by the color and texture of
the floor, i.e., D1: Discrimination 1 and D2: Discrimination 2. For each discrimination, only one hole out of the four holes of the apparatus was baited (hashed circles).
The two discrimination were separated by a 2 min delay interval during which animals are placed in room B. A 24-h delay was interpolated between the acquisition
and test phases, during which mice were returned in the colony room. 1 h prior to acquisition and test phases, mice received a per se administration of the
compounds or vehicle solution in a chamber placed in a room (room C) different from the one in which the behavioral experiments was conducted (room A).
Subsequently, mice were submitted to the test phase in which they were replaced on the floor of the first discrimination without any food pellet in the apparatus.
(B) Two types of responses were calculated: (i) correct responses corresponding to head-dips into the hole baited at the acquisition of the first discrimination (D1), on
the same floor context; (ii) interference responses corresponding to head-dips into the hole baited at the other (second) discrimination (D2). These two parameters
allow calculus of the SCM score.
(Figure 1B) and of the “strength” of “contextual memory” score
(SCM) (% correct responses - % interference responses). Thus,
since correct responses are based on the use of the internal
context (color of the floor) and interferent responses are based
on the use of spatial allocentric cues previously associated with
the other floor, thus the trend of SCM score toward a positive
difference represents the gain of internal contextual memory, at
the expense of allocentric spatial one.
Experiment 1: Effect of the Compounds
and Their Combinations on Age-Related
Memory Deficit
Drug Administration
S 38093 (Servier, France) and Donepezil (Syntheval, France) are
hydrochloride salts. S 38093 belongs to the chemical family of
benzamides, its hydrochloride salt S 38093-2 (called S 38093
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FIGURE 2 | Chemical formula of S 38093 (C17H24N2O2, HCl).
in the paper) was used in this study. Its chemical formula is
C17H24N2O2, HCl (Figure 2).
S 38093 and Donepezil were diluted in purified water. Mice
were allocated to administration of vehicle (purified water), S
38093 (S1: 0.1 mg/kg; S2: 0.3 mg/kg; S3: 1.0 mg/kg) or Donepezil
(Don1: 0.1 mg/kg; Don2: 0.3 mg/kg), or a combination of both
S 38093 and Donepezil at the same doses with N = 12 in each
group. S 38093 and Donepezil doses were determined according
to previous data (Béracochéa et al., 2008; Panayi et al., 2014).
Before behavioral testing, all mice received for nine consecutive
days a daily esophageal administration of S 38093, Donepezil,
vehicle or S 38093 + Donepezil combinations, administered at a
volume of 10 mL/kg. The two last administrations were delivered
1 h before the acquisition and test phases.
Pharmacokinetics Study
For the pharmacokinetics study, an additional day of treatment
(day 10) was done for blood sampling to measure concentrations
of S 38093 and Donepezil in plasma, on the combinations groups
where either the most important synergistic effect was observed,
or containing the highest doses of S 38093 and Donepezil. Then,
blood sampling (250 µL /sample) was performed on five groups
(N = 3 animals per group): S 38093 (0.1 and 1.0 mg/kg);
Donepezil (0.3 mg/kg); combination of Donepezil (0.3 mg/kg);
and S 38093 (0.1 and 1.0 mg/kg). The sampling times are 30 min,
1, 2, 4, and 6 h. In each mouse, two time points of blood sampling
were performed. Plasma was extracted from the blood sample
by centrifugation (+4◦C, 3000 g, 10 min) and stored at −80◦C.
Then, plasma samples were sent in dry ice to MDS (MDS Pharma
Services, Switzerland) for the pharmacokinetic analysis.
S 38093 and Donepezil were independently measured
by liquid chromatography using tandem mass spectrometry
detection (LC/MS–MS). Prior to analysis, S 38093 was extracted
from 25 µL of sample by solid phase extraction on an Isolute
96 CBA SPE 50 mg cartridge while Donepezil was extracted by
liquid/liquid extraction from a second 25 µl aliquot. The limit
of quantification was 0.3 ng/mL for S 38093 and 0.1 ng/mL for
Donepezil.
Animals were sacrificed by cervical elongation immediately
after either behavioral testing or plasma sampling.
Experiment 2: Study of the Effects of the
Compounds on Age-Related Memory
Deficit and CREB Phosphorylation
Behavioral Testing
Food deprivation, drug administration and behavioral testing
procedures were similar as in Experiment1. We performed
in Experiment 2 an immunohistochemical study on the
combination groups where either the most important synergistic
effect was observed (Don2+S1 and Don2+S2), or Vehicle,
S 38093 and Donepezil alone (Vehicle, S1, S2, and Don2).
Independent groups of mice (N = 10 per group) were used.
An additional group composed by young vehicle mice (4–
5 months young-vehicles, N = 10) was added for determination
of the aging effect on both memory and phosphorylated
CREB immunoreactivities, as compared to middle-aged
Vehicles. For the immunohistochemical study, animals
submitted to D1 memory testing were compared to “naïve”
mice isolated in the colony room (with N = 5 per group;
Naïve condition) and that underwent the food deprivation
procedure and drug treatments as behaving animals (Test
condition).
Immunohistochemistry
Thirty minutes after completion of the test session, mice were
deeply anesthetized (Avertin, 10 mL/kg intraperitoneally i.p.),
and perfused transcardially with an ice-cold solution of 4%
paraformaldehyde in phosphate buffer (0.1 M, pH 7.4). After
perfusion, brains were removed and post-fixed overnight in
the same fixative at 4◦C. Brains were then put in a sucrose
solution (30% in Tris Buffer 0.1 M, pH 7.4) during 24 h.
They were then frozen and cut in 50-mm coronal free-floating
sections with a freezing microtome (Leica) to proceed to
immunochemistry.
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FIGURE 3 | Effects of S 38093, Donepezil and combinations on SCM scores in middle-aged mice (Experiment 1). SCM scores are expressed as
mean ± SE. SCM scores are obtained by calculation (% of correct responses – % of interferent responses). As can be seen, the lowest S 38093 dose combined
with the highest Donepezil dose (DON 2 + S1), and inversely (DON 1 + S3), significantly increased SCM scores as compared to Vehicle and compounds alone.
∗∗p < 0.01 and ∗∗∗p < 0.001 as compared to vehicle; ##p < 0.05 and ###p < 0.01 respectively as compared to compounds alone.
Total CREB (tCREB) and phosphorylated CREB (pCREB)
immunostainings were performed as described in full previously
(Vandesquille et al., 2013; Dominguez et al., 2014, 2016).
Countings were made in the following brain regions according
to Paxinos and Franklin (2001) atlas: the CA1 of the dorsal
(dCA1) and ventral (vCA1) hippocampus, the prelimbic cortex
(PL), the dorsal striatum (St), the basolateral amygdala nucleus
(BLA) and the medial septum nucleus (MS). Digital images were
captured at 10X magnification using an Olympus (BX50) and
an imaging analysis system (ImageJ R©). At least six serial sections
for each brain region were analyzed using a computerized
image analysis system (Visiolab 2000 R©, Biocom, and V4.50).
Quantification was expressed as mean number of positive nuclei
per mm2.
Statistical Analysis
Behavioral data were analyzed by one-way or two-way factorial
analyses of variance, followed when adequate, by post hoc
(Dunnett test) comparisons using the least significant difference
test, with a p < 0.05 statistical threshold. Data were represented
as mean ± standard-error of the mean. For correlation analyses,
the Spearman’s correlation coefficient, R, was determined. For
immunohistochemistry, in so far as no difference was found
in the naïve condition, data were analyzed similarly using the
rough number of immunopositive cells, with a p < 0.05 statistical
threshold.
RESULTS
EXPERIMENT 1
Effect of the Compounds and Their Combinations on
Age-Related Memory Deficit
Body weights among the groups were ranged from 28.9 ± 3.5 to
32.4 ± 4.3 g and no significant between-groups difference was
observed [F(11,132) < 1.0]. During the food restriction period,
TABLE 1 | Mean pharmacokinetic parameters of S 38093 (0, 0.1, and
1.0 mg/kg) and Donepezil (0.3 mg/kg), given alone or in combination in
middle-aged mice (five groups, n = 3/group).
Dose 0 0.1 1
S 38093 AUC (ng.h/mL) – 9.56 3.69 92.40 53.90
Cmax (ng/mL) – 3.04 1.27 55.6 36.30
Tl/2(h) – 1.51 2.37 1.54
Tmax(ll) – 2.0 0.5 0.5 0.5
Dose 0.3 0 0.3 0 0.3
Donepezi AUC (ng.h/mL) 2.79 – 0.90 – 1.55
Cmax (ng/mL) 0.96 – 0.48 – 1.11
Tmax(ll) 1.0 – 0.5 – 0.5
The PK parameters of the co-administration of S 38093 (0.1 and 1.0 mg/kg) with
Donepezil (0.3 mg/kg) are in the gray columns.
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both vehicles and drug-treated mice eaten all their allocated daily
amount of dry food. All animals retained for the test session have
eaten at least 7/8 pellets out of 10 at both the first and second
acquisitions.
Acquisition phase
No significant difference was observed among the groups on the
total number of head-dips as well as on the % exploration of the
baited hole both at acquisitions 1 and 2 (p > 0.10 in all analyses).
Test phase
Total number of head-dips. The total number of head-dips ranged
from 31.2 ± 9.4 to 62.3 ± 9.4 and no significant between-groups
difference was observed [F(11,132) < 1.0]. The interaction (S
38093 X Donepezil) was also not significant [F(6,132) = 0.54,
p = 0.780]. Thus, the dose effect of S 38093 or Donepezil has
been analyzed at all levels pooled of the other drug. There was
no significant effect of either S 38093 [F(3,132)= 1.45, p= 0.231]
or Donepezil [F(2,132)= 0.28, p= 0.760] on this parameter.
Strength of contextual memory (SCM). Data are presented in
Figure 3. A one-way analysis of variance (ANOVA) showed a
highly significant between-groups difference [F(11,132) = 9.76;
p = 0.0001]. For compounds alone, S 38093 at 0.1 and 1.0 mg/kg
and Donepezil at all doses did not show significant effect on the
SCM scores as compared to the vehicle group (p > 0.10). For
combinations of compounds, except the combination of the two
lowest (Don at 0.1 mg/kg and S 38093 at 0.1 mg/kg) and the two
highest doses (Don at 0.3 mg/kg and S 38093 at 1.0 mg/kg) of each
compound, there was a strong, significant increase of SCM scores
(p < 0.01, p < 0.001, p < 0.001, and p < 0.01, respectively).
Pharmacokinetics Interaction
Results have been summarized in Table 1. The inter-individual
variability on S 38093 plasma concentrations was moderate.
Cmax was reached 0.5 h after dosing and the elimination half-life
was between 1.5 and 2.4 h. Both exposure and Cmax increase in a
dose proportional manner within the same treatment regimen.
Variability of Donepezil plasma concentrations following
concomitant administration of 0.3 mg/kg was moderate.
Maximal Donepezil plasma concentrations were observed
between 0.5 and 1 h after administration and were similar
with and without co-administration of S 38093. There was no
increase of neither S 38093 nor Donepezil plasma exposure when
administered as a combination.
Experiment 2: Study of the Effect of the
Compounds on Age-Related Memory
Deficit and CREB Phosphorylation
Body weights among the groups were ranged from 25.9 ± 2.8 g
(young adult mice) to 31.6 ± 4.1 g and no significant between-
groups difference was observed (p < 0.12). During the food
restriction period, both vehicles and drug-treated mice eaten
all the allocated daily amount of dry food. As in Experiment
1, all animals retained for the test session have eaten at
least 7/8 pellets out of 10 at both the first and second
acquisitions.
Effects of Aging on SCM Score and pCREB Activity
Behavior
Acquisition phase. No significant difference was observed among
the groups on the total number of head-dips as well as on the
% exploration of the baited hole both at acquisitions 1 and 2
[F(1,18) < 1.0 in all analyses; data not shown].
Test session
Effects of aging on SCM scores. Results are presented in Figure 4A.
Young adults and middle-aged animals exhibited a similar
total number of head-dips at the test session [30 ± 4.26 and
25.5± 4.05, respectively; Groups: F(1,18)< 1.0]. However, young
mice exhibited a positive score (+20.0 ± 3.6) whereas middle-
aged animals exhibited a negative one (−18.9 ± 7.9) [Groups;
F(1,18)= 18.92; p= 0.0004].
Immunohistochemistry
Effects of aging on tCREB and pCREB immunoreactivity. Results
are presented in Figure 4B. One way ANOVA evidenced
no significant difference (p > 0.10 in all analyses) between
young adult and middle-aged mice on the number of tCREB
immunopositive cells in naïve and test conditions, whatever
the brain areas counted (data not shown). Concerning pCREB,
one way ANOVA also evidenced no significant between-groups
difference in naïve condition on pCREB scores whatever the brain
areas counted (p > 0.10 in all analyses; data not shown).
Effects of Treatments on SCM Scores and pCREB
Activity in Middle-Aged Mice
Behavior
The group of young adult mice has been discarded from further
statistical analyses since the effects of the compounds alone or in
combination have been studied only in middle-aged animals.
Acquisition phase. No significant difference was observed among
the groups on the total number of head-dips as well as on the
% exploration of the baited hole both at acquisitions 1 and 2
[F(1,54) < 1.0 in all analyses; data not shown].
Test phase
Total number of head-dips. A significant between-groups
difference is observed [F(5,54) = 2.95; p = 0.02] being mainly
due to the S 0.3 mg/kg (44.90 ± 6.56) and S 0.1 mg/kg
(37.4 ± 6.15) groups. However, post hoc analyses failed to
reach the statistical level of significance for these two groups as
compared to either vehicles (25.50 ± 4.05; p > 0.10) or Don
0.3 mg/kg (23.90 ± 4.06; p > 0.15). The groups receiving the
doses combinations (Don 0.3 mg/kg+ S 0.1 mg/kg: 21.90± 3.42;
Don 0.3 mg/kg + S 0.3 mg/kg: 29.10 ± 6.06) exhibited a total
number of head-dips similar to that of vehicles (p > 0.10).
Strength of contextual memory. Data are represented in
Figure 5. ANOVA evidenced significant effects of Donepezil
[F(1,54) = 48.88; p < 0.0001], of S 38093 [F(2,54) = 7.49;
p = 0.0013] and of the interaction between Donepezil and S
38093 [F(2,54) = 5.57; p = 0.0063]. Donepezil (+7.48 ± 3.60)
and S 38093 at the doses of 0.3 mg/kg (+5.19 ± 6.68) and
0.1 mg/kg (−14.3 ± 5.76) produced no significant modifications
of the scores as compared to vehicle (−18.14 ± 7.9; NS in
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FIGURE 4 | (A) Effects of aging on SCM scores (Experiment 2). As can be seen, 14 months-old middle-aged mice exhibited a significant reduction of SCM score as
compared to 5 months-old young-adult mice. Between-groups difference: ∗∗∗p < 0.001. (B) Effects of aging on pCREB immunoreactivities. Counting was made in
the PFC, dCA1, vCA1, medial septum, dorsal striatum, and BLA. No significant differences were observed between the groups in all brain areas in naïve condition
(data not shown). Middle-aged mice showed reduced behavioral testing-related pCREB immunoreactivities in the dCA1, vCA1, and medial septum as compared to
young adult mice. In contrast, a significant increase of pCREB was observed in the BLA in middle-aged animals, as compared to young ones. Results are expressed
as mean number of positive pCREB nuclei per mm2. ∗p < 0.05, ∗∗p < 0.01.
all comparisons). However, the higher positive scores were
observed in groups receiving the combinations of Donepezil and
S 38093 at the doses of 0.1 mg/kg (+43.59 ± 7.10; p < 0.001
versus vehicle and p < 0.01 versus the Donepezil group) and
0.3 mg/kg (+25.73 ± 3.96; p < 0.01 versus vehicle; NS versus
Donepezil). Thus, only the combination of Donepezil and S
38093 at 0.1 mg/kg produced a significant increase of SCM
score as compared to both vehicle-treated mice and Don
0.3 mg/kg.
In contrast, significant differences were observed in test
condition (Figure 5). More specifically, middle-aged mice
exhibited less immunopositive cells as compared to young
animals in the dCA1 (−47.5%; p = 0.007), the vCA1 (−56%;
p= 0.0037), and the MS (−66.2%; p= 0018). A weak increase of
immunopositive cells is observed in the BLA of middle-aged mice
(+32.7%; p = 0.039). No significant between-groups difference
was observed in the PFC and the dorsal striatum.
Effects of treatments on tCREB and pCREB
immunoreactivity in middle-aged mice
Total CREB. Analysis of variance analyses showed no significant
between-groups difference, no treatments effect and no
significant interaction between drugs were found both in naïve
and test conditions (p > 0.10 in all analyses; data not shown).
Phosphorylated CREB. In naïve condition, no significant
between-groups difference, no treatments effect and no
significant interaction between drugs was found whatever the
brain structure counted (p > 0.10 in all analyses; data not
shown).
In test condition (Figure 6A), no significant between-groups
difference and no significant interaction between drugs were
observed in the BLA, the dorsal striatum and the vCA1 (p > 0.10
in all analyses). However, donepezil induced a significant
increase of immunopositive cells in the dCA1 [F(1,54) = 11.2;
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FIGURE 5 | Effects of S 38093, Donepezil and combinations on SCM scores in middle-aged mice (Experiment 2). SCM scores are expressed as
mean ± SE. SCM scores are obtained by calculation (% of correct responses – % of interferent responses). As can be seen, the lowest S 38093 dose combined
with Donepezil significantly increased SCM scores as compared to Vehicle and compounds (Donepezil and S 38093) alone. Combination of Donepezil and the
higher S 38093 dose induced a significant increase of SCM score as compared to vehicle only. ∗∗p < 0.01 and ∗∗∗p < 0.001 as compared to vehicle; ##p < 0.01 as
compared to Donepezil and S 38093 alone.
p < 0.001] and in the MS [F(1,54) = 18.3; p < 0.001]. S
38093 at both doses has no significant effect in these two
brain areas. Two way ANOVA also showed that S38093 and
Donepezil have a significant interaction effect in the dCA1
[F(2,54) = 3.57; p < 0.03] and the interaction is near from
statistical significance in the MS [F(2,54) = 3.0; p = 0.058].
Figure 6B illustrated changes in pCREB activity in the dCA1
of the hippocampus in the different groups in naïve and test
conditions.
Calculus in percentage of the enhancement of pCREB in the
combination groups as compared to compounds alone or vehicles
were performed. The main findings are as follows:
In the BLA, Dunnett post hoc test evidenced a significant
increase of pCREB expression in mice receiving S 0.1 mg/kg
+Don 0.3 mg/kg (+60.9%) in comparison with S 0.1 mg/kg alone
(p < 0.01).
In the dCA1, results showed a significant increase of pCREB
expression in mice receiving the combination S 0.1 mg/kg+
Don 0.3 mg/kg (+129.4%) and in mice receiving S 0.3 mg/kg+
Don0.3 mg/kg (+64.7%; p < 0.01) as compared to vehicle.
More importantly, for the group receiving the combination
S 0.1 mg/kg+Don0.3 mg/kg, a significant increase of pCREB
expression of +192.7% has been evidenced as compared to S
0.1 mg/kg alone (p < 0.01) and of +137.1% in comparison with
Donepezil alone (p < 0.01).
In the MS, Donepezil alone as well as the combination S
0.1 mg/kg+ Don 0.3 mg/kg induced a significant increase of
pCREB expression of +174.3% and +214.1% respectively as
compared to vehicle. A significant increase of +380.7% has also
been evidenced between S 0.1 mg/kg alone and the combination
S 0.1+ Don 0.3 mg/kg.
DISCUSSION
Synergistic Effects between Donepezil
and S 38093 on Contextual Memory in
Middle-Aged Mice
As regards SCM scores, vehicle-treated middle-aged mice showed
a negative score on the retention of D1 (indicating an increase
of interferent responses) in sharp contrast to young adult mice
which exhibited a very positive score. In contrast, compounds
alone or in combination (excepted for the combinations of
the two lowest and the two highest doses of each compound)
reverse this age-related memory pattern, as those mice have
a substantial memory of D1 but not of D2 as compared to
vehicle-treated animals. Since it has been shown that memory
of D1 is hippocampus-dependent (Chauveau et al., 2008, 2010)
whereas memory of D2 is dependent on the PFC activity
(Chauveau et al., 2009), it is thus of importance to verify that
any promnesiant impact of the combinations of compounds
on D1 did not alter memory of D2. This effect, statistically
significant for the combinations with the exception quoted above,
is the index of a substantial contextual memory-enhancing effect
since the increase of the correct response is accompanied by
a concomitant decrease of the interference one. Interestingly,
the more powerful combination is observed with the lowest
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FIGURE 6 | Effects of S 38093, Donepezil and combinations on pCREB immunoreactivities in middle-aged mice. (A) Counting was made in the PFC,
dCA1, vCA1, medial septum, dorsal striatum, and BLA. No significant differences were observed between the groups in all brain areas in naïve condition (data not
shown). As can be seen, the lowest S 38093 dose combined with Donepezil significantly increased pCREB immunopositive cells as compared to vehicles and
compounds (Donepezil and S 38093) alone. A significant increase of immunopositive cells was also observed in the BLA with the same combination as compared to
compounds alone (Donepezil or S 38093). Combination of Donepezil and the higher S 38093 dose induced a significant increase of pCREB immunopositive cells as
compared to vehicles only. ∗p < 0.05 and ∗∗∗p < 0.001 as compared to vehicles; ##p < 0.01 as compared to Donepezil and •p < 0.05 as compared to S 38093
alone. (B) Representative photomicrographs showing pCREB immunoreactivities in the dCA1 of the hippocampus in young adult and middle-aged mice after
administration of S 38093 (0.1 and 0.3 mg/kg), Donepezil (0.3 mg/kg) and combinations both in naïve and test conditions. Magnification X20, Scale bar: 50 µm.
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S 38093 dose + Donepezil 0.3 mg/kg since this combination
induced a significant enhancement of contextual memory as
regards to both Donepezil and S 38093 alone. It is noteworthy that
combination of S 38093 with low pro-cognitive doses of any other
compound currently approved for moderate-to-severe AD [i.e.,
others AChEI (rivastigmine and galantamine) and memantine,
an uncompetitive NMDA (N-methyl-D-aspartate) antagonist]
also leads to higher reversal of age-related memory deficit in this
task compared to compounds alone (unpublished results, data
not shown). Moreover, there was a very good correlation between
the increase of percentage of correct responses and the decrease
of percentage of interferent responses, confirming the specific
effect of each compound and their combinations on contextual
memory (data not shown).
Interestingly, a synergistic effect between a H3 antagonist
and an anti-cholinesterase inhibitor has also been described in
cognitive impairment associated with scopolamine in healthy
young subjects (Cho et al., 2011). Our data showing synergistic
effects between the H3 antagonist S 38093 and drugs approved in
AD are innovative since, to our knowledge, that has never been
described for other H3 compounds nor procognitive compounds
on natural model of age-induced amnesia in rodents.
As the two compounds were administered simultaneously, it
was important to assess a potential pharmacokinetic interaction,
which could have faked a synergistic effect by increasing the
blood exposure. Our study confirmed that the synergistic effect
of the combination of the two compounds is not due to a
pharmacokinetic interaction between them. Moreover, the safety
of S 38093 and Donepezil, alone or in combination, was tested
using the primary observation (IRWIN) test in mice and results
showed that the combination of pharmacological doses of both
compounds did not induce any observable clinical signs, similarly
as compounds administered alone (data not shown).
Synergistic Effects between Donepezil
and S 38093 on pCREB Immunoreactivity
in the Dorsal Hippocampus and the
Medial Septum
Aging reduced pCREB in the dCA1, the vCA1 and the MS as
compared to young vehicle, whereas an increase of pCREB is
observed in the BLA. These data confirm that alterations of
the hippocampus activity induced contextual memory deficit
in middle-aged animals (Béracochéa et al., 2011). Interestingly,
we also previously showed that the BLA and the mPFC are
importantly involved in the memory retrieval of D2 (Chauveau
et al., 2009; Dominguez et al., 2014). Thus, the increase of
pCREB in the BLA during memory retrieval of D1 could reflect
an abnormal concomitant recruitment of a BLA-PFC network
in middle-aged animals which could increase interference (D2)
responses.
Whereas no significant between-groups difference is observed
in the naive condition, S 38093 and Donepezil have a significant
synergistic effect in the dCA1 and near significant effect in the
MS, as compared to each compound alone. More precisely, the
combination of S 0.1 mg/kg and Donepezil 0.3 mg/kg reverses
in the dCA1 the age-induced hypo-phosphorylation of pCREB.
This combination is also the most efficacious in reversing the age-
induced memory retrieval deficit for D1, as previously reported.
Hypothesis on the Mechanism of Action
Immunohistochemical data show that the combination of S
0.1 mg/kg and Don 0.3 mg/kg increases pCREB in structures
of the cholinergic septo-hippocampal loop. Indeed, the medial
septal area provides most of the cholinergic innervation of the
hippocampus (Jakab and Septum, 1995; Mamad et al., 2015).
Thus, one hypothesis regarding the mechanisms of action
of the compounds is an effect on the hippocampal cholinergic
system. Indeed, in separate experiments, we showed that the
acute as well as chronic administration of S 38093 in rats, by
antagonizing presynaptic H3 receptors, has been shown to rapidly
and dose-dependently increase the release of ACh in the ventral
hippocampus and the PFC of rats (intracerebral microdialysis, see
supplemental data and Panayi et al., 2014). On the other hand, the
well-known AChEI Donepezil, given alone, also increased ACh
level in the synaptic cleft after acute administration. Previous
studies have also confirmed that the increase in ACh levels
induced by Donepezil in the cortex and hippocampus of rats are
maintained after chronic administration (Scali et al., 2002). Either
action could result in the observed enhancement of contextual
memory with compounds alone, whereas the stronger effect of
the combinations could be attributed to a synergistic effect on the
hippocampal cholinergic system, including the additive effect on
ACh release of the compounds observed in microdialysis when S
38093 and Donepezil were administered together (Supplemental
Data, see Figures 1 and 2). Thus the microdialysis experiment
evidenced the potential capacity of S 38093 and Donepezil to
enhance the cholinergic activity within the hippocampo-PFC
network that is substantially implicated in the CSD task.
Even if the effect of the compounds were evaluated in the
PFC and the ventral hippocampus in supplemental data, it was
also demonstrated that H3 antagonists including S 38093 (data
no shown) as well as Donepezil were also able to significantly
increase ACh levels in other brain areas and in particular dorsal
hippocampus (Medhurst et al., 2007; Herrik et al., 2016), a critical
region for memory processes, in which we have demonstrated
pCREB increases in the present study.
Mice treated with the combination of the two highest
doses of S 38093 and Donepezil showed impairments in the
retrieval of D1. It could be hypothesized that this combination
induces an important increase of acetylcholine levels both in the
hippocampus and PFC, which could alter the interaction between
these two areas during the testing of D1, leading to memory
impairment. Indeed, the concomitant recruitment of the PFC
by acetylcholine in mice receiving the drug combinations could
enhance interference (D2) responses (Chauveau et al., 2009), at
the expense of the dHPC-dependent one (D1).
CONCLUSION
The present study shows that the combination of the two
memory-enhancing compounds, Donepezil and the H3
antagonist S 38093, can lead to synergistic memory-enhancing
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effects, with a statistically higher size of effect never obtained
with any memory-enhancing compounds alone without any
pharmacokinetic interaction between both compounds. The
memory-enhancing effect of the S 38093 and Donepezil
combination is mediated by its action on the septo-hippocampal
circuitry, since it canceled out the hypo-phosphorylation of
pCREB in both the dCA1 and the medial septum that is observed
in vehicle-treated middle-aged mice. Given the known pro-
cholinergic effects of histaminergic H3 inverse agonists and
Donepezil (Schwartz and Lecomte, 2016) and our own data
drawn from the microdialysis experiment (supplemental data), it
could be suggested that the synergistic effects of the combination
of S 38093 and Donepezil on memory performance in middle-
aged mice could stem from an enhancement of the septo-
hippocampal cholinergic system.
AUTHOR CONTRIBUTIONS
DB: planning pharmacological and immunohistochemical
experiments and writing of the manuscript; AS: planning
pharmacological experiments and writing of the manuscript; JK:
planning biochemical experiments; TY: planning and running
microdialysis experiments; GD: running immunohistochemical
experiments; ND: running immunohistochemical experiments;
CL: planning of experiments and supervising the study;
EM: supervisor and writing of the manuscript; AK: running
pharmacological experiments.
FUNDING
Institut de Recherches Internationales Servier (IRIS), Suresne,
France.
ACKNOWLEDGMENTS
The authors thank MDS (MDS PharmaServices, Allmendstrasse
32, AG8320 Fehraltorf, Switzerland) for the pharmacokinetic
study. This work has also benefited from the facilities and
expertise of the “Integrated Microscopy Facility platform”
(www.incia.u-bordeaux1.fr) which is supported by CNRS and
Region Aquitaine.
SUPPLEMENTARY MATERIAL
The Supplementary Material for this article can be found
online at: http://journal.frontiersin.org/article/10.3389/fphar.
2016.00492/full#supplementary-material
REFERENCES
Arrang, J. M., Garbarg, M., and Schwartz, J. C. (1983). Auto-inhibition of brain
histamine release mediated by a novel class (H3) of histamine receptor. Nature
302, 832–837. doi: 10.1038/302832a0
Barsegyan, A., Mackenzie, S. M., Kurose, B. D., McGaugh, J. L., and Roozendaal, B.
(2010). Glucocorticoids in the prefrontal cortex enhance memory consolidation
and impair working memory by a common neural mechanism. Proc. Natl. Acad.
Sci. U.S.A. 107, 16655–16660. doi: 10.1073/pnas.1011975107
Bartus, R. T., Dean, R. L. III, Beer, B., and Lippa, A. S. (1982). The cholinergic
hypothesis of geriatric memory dysfunction. Science 217, 408–414. doi: 10.1126/
science.7046051
Baudonnat, M., Guillou, J. L., Husson, M., Vandesquille, M., Corio, M., Decorte, L.,
et al. (2011). Disrupting effect of drug-induced reward on spatial but not cue-
guided learning: implication of the striatal protein kinase A/cAMP response
element-binding protein pathway. J. Neurosci. 31, 16517–16528. doi: 10.1523/
JNEUROSCI.1787-11.2011
Benito, E., and Barco, A. (2010). CREB’s control of intrinsic and synaptic plasticity:
implications for CREB-dependent memory models. Trends Neurosci. 33, 230–
240. doi: 10.1016/j.tins.2010.02.001
Béracochéa, D., Philippin, J. N., Meunier, S., Morain, P., and Bernard, K. (2007).
Improvement of episodic contextual memory by S 18986 in middle-aged mice:
comparison with donepezil. Psychopharmacology 193, 63–73. doi: 10.1007/
s00213-007-0765-4
Béracochéa, D., Philippin, J. N., Meunier, S., Morain, P., and Bernard, K. (2008).
Improvement of episodic contextual memory by S 18986 in middle-aged mice:
comparison with Donepezil. Psychopharmacology 196, 555–564. doi: 10.1007/
s00213-007-0987-5
Béracochéa, D., Tronche, C., Coutan, M., Dorey, R., Chauveau, F., and Piérard, C.
(2011). Interaction between Diazepam and hippocampal corticosterone after
acute stress: impact on memory in middle-aged mice. Front. Behav. Neurosci.
12:14. doi: 10.3389/fnbeh.2011.00014
Bernabeu, R., Bevilaqua, L., Ardenghi, P., Bromberg, E., Schmitz, P., Bianchin, M.,
et al. (1997). Involvement of hippocampal cAMP/cAMPdependent protein
kinase signaling pathways in a late memory consolidation phase of aversively
motivated learning in rats. Proc. Natl. Acad. Sci. U.S.A. 94, 7041–7046. doi:
10.1073/pnas.94.13.7041
Blandina, P., Giorgetti, M., Bartolini, L., Cecchi, M., Timmerman, H., Leurs, R.,
et al. (1996). Inhibition of cortical acetylcholine release and cognitive
performance by histamine H3 receptor activation in rats. Br. J. Pharmacol. 119,
1656–1664. doi: 10.1111/j.1476-5381.1996.tb16086.x
Brown, R. E., Stevens, D. R., and Haas, H. L. (2001). The physiology of brain
histamine. Prog. Neurobiol. 63, 637–672. doi: 10.1016/S0301-0082(00)00039-3
Chauveau, F., Piérard, C., Coutan, M., Drouet, I., Liscia, P., and Béracochéa, D.
(2008). Prefrontal cortex or basolateral amygdala lesions blocked the stress-
induced inversion of serial memory retrieval pattern in mice. Neurobiol. Learn.
Mem. 90, 395–403. doi: 10.1016/j.nlm.2008.04.014
Chauveau, F., Pierard, C., Tronche, C., Coutan, M., Drouet, I., Liscia, P., et al.
(2009). The hippocampus and prefrontal cortex are differentially involved in
serial memory retrieval in non-stress and stress conditions. Neurobiol. Learn.
Mem. 91, 447–455. doi: 10.1016/j.nlm.2008.12.003
Chauveau, F., Tronche, C., Piérard, C., Liscia, P., Drouet, I., Coutan, M., et al.
(2010). Rapid stress-induced corticosterone rise in the hippocampus reverses
serial memory retrieval pattern. Hippocampus 20, 196–207. doi: 10.1002/hipo.
20605
Cho, W., Maruff, P., Connell, J., Gargano, C., Calder, N., Doran, S., et al. (2011).
Additive effects of a cholinesterase inhibitor and a histamine inverse agonist
on scopolamine deficits in humans. Psychopharmacology (Berl.). 218, 513–524.
doi: 10.1007/s00213-011-2344-y
Colombo, P. J., Brightwell, J. J., and Countryman, R. A. (2003). Cognitive strategy-
specific increases in phosphorylated cAMP response element-binding protein
and c-Fos in the hippocampus and dorsal striatum. J. Neurosci. 23, 3547–3554.
Dominguez, G., Dagnas, M., Decorte, L., Vandesquille, M., Belzung, C.,
Béracochéa, D., et al. (2016). Rescuing prefrontal camp-creb pathway reverses
working memory deficits during withdrawal from prolonged alcohol exposure.
Brain Struct. Funct. 221, 865–877. doi: 10.1007/s00429-014-0941-3
Dominguez, G., Faucher, P., Henkous, N., Krazem, A., Piérard, C., and
Béracochéa, D. (2014). Stress induced a shift from dorsal hippocampus to
prefrontal cortex dependent memory retrieval: role of regional corticosterone.
Front. Behav. Neurosci. 8:166. doi: 10.3389/fnbeh.2014.00166
Frontiers in Pharmacology | www.frontiersin.org 11 December 2016 | Volume 7 | Article 492
fphar-07-00492 December 20, 2016 Time: 19:4 # 12
Sors et al. Donepezil and H3 Antagonist Interaction
Femenía, T., Magara, S., DuPont, C. M., and Lindskog, M. (2015). Hippocampal-
dependent antidepressant action of the H3 receptor antagonist clobenpropit
in a rat model of depression. Int. J. Neuropsychopharmacol. 18, yv032. doi:
10.1093/ijnp/pyv032
Fernández-Novoa, L., and Cacabelos, R. (2001). Histamine function in brain
disorders. Behav. Brain Res. 124, 213–233. doi: 10.1016/S0166-4328(01)00215-7
Fox, G. B., Pan, J. B., Radek, R. J., Lewis, A. M., Bitner, R. S., Esbenshade, T. A.,
et al. (2003). Two novel and selective nonimidazole H3 receptor antagonists
A-304121 and A-317920: II. In vivo behavioral and neurophysiological
characterization. J. Pharmacol. Exp. Ther. 305, 897–908.
Francis, P. T., Ramírez, M. J., and Lai, M. K. (2010). Neurochemical basis for
symptomatic treatment of Alzheimer’s disease. Neuropharmacology 59, 221–
229. doi: 10.1016/j.neuropharm.2010.02.010
Fu, A., Zhou, R., and Xu, X. (2014). The synthetic thyroid hormone, levothyroxine,
protects cholinergic neurons in the hippocampus of naturally aged mice. Neural
Regen. Res. 15, 864–871. doi: 10.4103/1673-5374.131602
Herrik, K. F., Mørk, A., Richard, N., Bundgaard, C., Bastlund, J. F., and de Jong,
I. E. (2016). The 5-HT6 receptor antagonist idalopirdine potentiates the
effects of acetylcholinesterase inhibition on neuronal network oscillations
and extracellular acetylcholine levels in the rat dorsal hippocampus.
Neuropharmacology 107, 351–363. doi: 10.1016/j.neuropharm.2016.
03.043
Jakab, R. L., and Septum, L. C. (1995). “The hippocampal formation,” in The Rat
Nervous System, 2nd Edn, ed. G. Paxinos (Cambridge, MA: Academic Press),
405–442.
Johannsson, M., Snaedal, J., Johannesson, G. H., Gudmundsson, T. E., and
Johnsen, K. (2015). The acetylcholine index: an electroencephalographic
marker of cholinergic activity in the living human brain applied to Alzheimer’s
disease and other dementias. Dement. Geriatr. Cogn. Disord. 39, 132–142. doi:
10.1159/000367889
Ligneau, X., Landais, L., Perrin, D., Piriou, J., Uguen, M., Denis, E., et al.
(2007). Brain histamine and schizophrenia: potential therapeutic applications
of H3-receptor inverse agonists studied with BF2.649. Biochem. Pharmacol. 73,
1215–1224. doi: 10.1016/j.bcp.2007.01.023
Lim, Y. Y., Maruff, P., Schindler, R., Ott, B. R., Salloway, S., Yoo, D. C., et al. (2015).
Disruption of cholinergic neurotransmission exacerbates Aβ-related cognitive
impairment in preclinical Alzheimer’s disease. Neurobiol. Aging 36, 2709–2715.
doi: 10.1016/j.neurobiolaging.2015.07.009
Lockhart, B. P., and Lestage, P. J. (2003). Cognition enhancing or neuroprotective
compounds for the treatment of cognitive disorders: why? when? which? Exp.
Gerontol. 38, 119–128. doi: 10.1016/S0531-5565(02)00163-8
Mamad, O., McNamara, H. M., Reilly, R. B., and Tsanov, M. (2015). Medial septum
regulates the hippocampal spatial representation. Front. Behav. Neurosci.
30:166. doi: 10.3389/fnbeh.2015.00166
Marighetto, A., Valerio, S., Desmedt, A., Philippin, J. N., Trocmé-Thibierge, C., and
Morain, P. (2008). Comparative effects of the alpha7 nicotinic partial agonist, S
24795, and the cholinesterase inhibitor, Donepezil, against aging-related deficits
in declarative and working memory in mice. Psychopharmacology (Berl.). 197,
499–508. doi: 10.1007/s00213-007-1063-x
Medhurst, A. D., Atkins, A. R., Beresford, I. J., Brackenborough, K., Briggs, M.
A., Calver, A. R., et al. (2007). GSK189254, a novel H3 receptor antagonist that
binds to histamine H3 receptors in Alzheimer’s disease brain and improves
cognitive performance in preclinical models. J. Pharmacol. Exp. Ther. 321,
1032–1045. doi: 10.1124/jpet.107.120311
Panayi, F., Sors, A., Bert, L., Martin, B., Rollin-Jego, G., Billiras, R., et al. (2014). “In
vivo pharmacological profile of S 38093, a novel inverse agonist at histamine
H3 receptors,” in Poster at the Neuroscience Meeting Planner: Program N◦
21.08SA/UU28. (Washington, DC: Society for Neuroscience).
Paxinos, G., and Franklin, K. B. J. (2001). The Mouse Brain in Stereotaxic
Coordinates, 2nd Edn. Cambridge, MA: Academic Press.
Runyan, J. D., and Dash, P. K. (2005). Distinct prefrontal molecular mechanisms
for information storage lasting seconds versus minutes. Learn. Mem. 12, 232–
238. doi: 10.1101/lm.92405
Scali, C., Casamenti, F., Bellucci, A., Costagli, C., Schmidt, B., and Pepeu, G. (2002).
Effect of subchronic administration of metrifonate, rivastigmine and donepezil
on brain acetylcholine in aged F344 rats. J. Neural. Transm. (Vienna). 109,
1067–1080. doi: 10.1007/s007020200090
Schwartz, J. C. (2011). The histamine H3 receptor: from discovery to clinical trials
with pitolisant. Br. J. Pharmacol. 163, 713–721. doi: 10.1111/j.1476-5381.2011.
01286.x
Schwartz, J. C., and Lecomte, J. M. (2016). Clinical trials with H3-receptor inverse
agonists: what they tell us about the role of histamine in the human brain.
Neuropharmacology 106, 35–36. doi: 10.1016/j.neuropharm.2016.04.006
Tronche, C., Lestage, P., Louis, C., Carrie, I., and Béracochéa, D. (2010).
Pharmacological modulation of contextual “episodic-like” memory in aged
mice. Behav. Brain Res. 215, 255–260. doi: 10.1016/j.bbr.2010.04.009
Vandesquille, M., Baudonnat, M., Decorte, L., Louis, C., Lestage, P., and
Béracochéa, D. (2013). Working memory deficits and related disinhibition of
the cAMP/PKA/CREB are alleviated by prefrontal α4β2∗-nAChRs stimulation
in aged mice. Neurobiol. Aging 34, 1599–1609. doi: 10.1016/j.neurobiolaging.
2012.10.006
Witkin, J. M., and Nelson, D. L. (2004). Selective histamine H3 receptor antagonists
for treatment of cognitive deficiencies and other disorders of the central
nervous system. Pharmacol. Ther. 103, 1–20. doi: 10.1016/j.pharmthera.2004.
05.001
Conflict of Interest Statement: These studies were financially supported by Servier
(Suresnes, France). AS and EM are currently employees of Servier. All the other
authors declare that the research was conducted in the absence of any commercial
or financial relationships that could be construed as a potential conflict of interest.
Copyright © 2016 Sors, Krazem, Kehr, Yoshitake, Dominguez, Henkous, Letondor,
Mocaer and Beracochea. This is an open-access article distributed under the terms
of the Creative Commons Attribution License (CC BY). The use, distribution or
reproduction in other forums is permitted, provided the original author(s) or licensor
are credited and that the original publication in this journal is cited, in accordance
with accepted academic practice. No use, distribution or reproduction is permitted
which does not comply with these terms.
Frontiers in Pharmacology | www.frontiersin.org 12 December 2016 | Volume 7 | Article 492
